Dynavax Technologies (NASDAQ:DVAX) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Other equities research analysts have also recently issued reports about the company. Cowen reiterated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Thursday, August 10th. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. William Blair reiterated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $28.00 target price (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Finally, Cantor Fitzgerald raised their target price on Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $25.17.

Shares of Dynavax Technologies (DVAX) traded down $1.60 on Friday, reaching $18.40. The company had a trading volume of 1,908,637 shares, compared to its average volume of 2,297,730. Dynavax Technologies has a 52-week low of $3.70 and a 52-week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm’s quarterly revenue was down 68.8% compared to the same quarter last year. During the same period last year, the business posted ($0.90) earnings per share. analysts predict that Dynavax Technologies will post -1.72 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of DVAX. Parametric Portfolio Associates LLC raised its stake in shares of Dynavax Technologies by 3.6% during the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 939 shares in the last quarter. American International Group Inc. raised its stake in shares of Dynavax Technologies by 7.1% during the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 1,584 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Dynavax Technologies by 14.4% during the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock valued at $10,864,000 after purchasing an additional 230,373 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Dynavax Technologies by 6.6% during the first quarter. Geode Capital Management LLC now owns 290,958 shares of the biopharmaceutical company’s stock valued at $1,731,000 after purchasing an additional 18,012 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Dynavax Technologies by 23.7% during the first quarter. Renaissance Technologies LLC now owns 574,051 shares of the biopharmaceutical company’s stock valued at $3,416,000 after purchasing an additional 110,100 shares in the last quarter. Institutional investors and hedge funds own 70.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies (DVAX) Downgraded to Sell at ValuEngine” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/03/dynavax-technologies-dvax-downgraded-to-sell-at-valuengine.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.